Board Unanimously Recommends Shareholders Approve the Sale of MDS Analytical Technologies
The Management Proxy Circular contains important information about MDS Inc. and the sale, as well as information related to voting procedures at the Special Meeting of Shareholders. A copy of the Management Proxy Circular will also be filed today with the Canadian Securities Administrators and the U.S. Securities and Exchange Commission, and will be available on their respective Websites at www.sedar.com or www.sec.gov/edgar.shtml, and at the Company's Website at www.mdsinc.com. Shareholders are urged to read the Management Proxy Circular in its entirety.
The purchase price to be paid to MDS Inc. for the sale of its MDS Analytical Technologies business is
The MDS Inc. Board of Directors believes the sale, which was announced on
About MDS
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information: For further information: MEDIA: Janet Ko, (905) 267-4226, [email protected]; INVESTORS: Peter Dans, (905) 267-4230, [email protected]
Share this article